Oral Nirmatrelvir and Ritonavir for Coronavirus Disease 2019 in Vaccinated, Nonhospitalized Adults Aged 18–50 Years
Clinical Infectious Diseases · 11.11.2023 · 77 (9) · 1257-1264
DOI: 10.1093/cid/ciad400 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 30.06.2023. Verfasst von Jeremy Samuel Faust und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Health Policy and Public Health, Department of Emergency Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massa…. Hauptthemen laut MEDLINE: COVID-19, Asthma, Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Background
The effects of nirmatrelvir/ritonavir (NMV/r [Paxlovid]) on coronavirus disease 2019 (COVID-19) outcomes in younger vaccinated adults are unclear. The objective of this study was to assess if NMV/r use in vaccinated adults aged ≤50 years is associated with improved outcomes and to identify beneficial and nonbeneficial subgroups.
Methods
In this cohort study, we generated 2 propensity-matched cohorts of 2547 patients from an 86 119-person cohort assembled from the TriNetX database. Patients in 1 cohort received NMV/r, and patients in the matched control cohort did not. The main outcome was composite of all-cause emergency department visits, hospitalization, and mortality.
Results
The composite outcome was detected in 4.9% of the NMV/r cohort and 7.0% of the non-NMV/r cohort (odds ratio, 0.683 [95% confidence interval, .540–.864]; P = .001), indicating a 30% relative risk reduction. The number needed to treat (NNT) for the primary outcome was 47. Subgroup analyses found significant associations for patients with cancer (NNT = 45), cardiovascular disease (NNT = 30), and both conditions (NNT = 16). No benefit was found for patients with only chronic lower respiratory disorders (asthma/chronic obstructive pulmonary disease [COPD]) or without serious comorbidities. Thirty-two percent of NMV/r prescriptions in the overall database were for 18- to 50-year-olds.
Conclusions
NMV/r use in vaccinated adults aged 18–50 years, especially with serious comorbidities, was associated with reduced all-cause hospital visits, hospitalization, and mortality in the first 30 days of COVID-19 illness. However, NMV/r in patients without significant comorbidities or with only asthma/COPD had no association of benefit. Therefore, identifying high-risk patients should be a priority and overprescription should be avoided.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Health Policy and Public Health, Department of Emergency Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Department of Medicine, Cleveland Clinic Akron General, Akron, Ohio, USA.
- Division of Cardiovascular Medicine, Department of Medicine, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, Vermont, USA.
- Division of Infectious Disease, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Jeremy Samuel Faust, Sarju Ganatra
Zitieren
APA
Faust, J. S., Kumar, A., Shah, J., Khadke, S., Dani, S. S., Ganatra, S., & Sax, P. E. (2023). Oral Nirmatrelvir and Ritonavir for Coronavirus Disease 2019 in Vaccinated, Nonhospitalized Adults Aged 18–50 Years. Clinical Infectious Diseases, 77(9), 1257-1264. https://doi.org/10.1093/cid/ciad400
Vancouver
Faust JS, Kumar A, Shah J, Khadke S, Dani SS, Ganatra S, et al. Oral Nirmatrelvir and Ritonavir for Coronavirus Disease 2019 in Vaccinated, Nonhospitalized Adults Aged 18–50 Years. Clinical Infectious Diseases. 2023;77(9):1257-1264. doi:10.1093/cid/ciad400
BibTeX
@article{Faust2023,
author = {Faust, Jeremy Samuel and Kumar, Ashish and Shah, Jui and Khadke, Sumanth and Dani, Sourbha S and Ganatra, Sarju and Sax, Paul E},
title = {Oral Nirmatrelvir and Ritonavir for Coronavirus Disease 2019 in Vaccinated, Nonhospitalized Adults Aged 18–50 Years},
journal = {Clinical Infectious Diseases},
year = {2023},
volume = {77},
number = {9},
pages = {1257--1264},
doi = {10.1093/cid/ciad400}
}
EUVIMED